Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn
Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with …
Post
-
-
AI-powered orchestration: Bringing the benefits to personalized therapy
Cell and gene therapies represent a groundbreaking advancement in medical science, offering transformative opportunities for treating complex and previously untreatable …
-
European pharma needs scalable models to succeed in US
European companies must be able to provide developed and scalable business models if they want to enter the US to …
-
Averoa secures EC authorisation for oral CKD treatment
The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney disease (CKD), a condition …
-
European biotech ecosystem takes aim at changing the funding narrative
“The science is brilliant in Europe, but the translation is what’s lacking,” said V-Bio Ventures managing partner Christina Takke on …
-
Ex-ACIP panel warns of ‘critically weakened’ US immunisation programme
Sweeping changes made by US health secretary Robert F Kennedy, Jr (RFK Jr) at the Centers for Disease Control and …
-
Teva to collaborate with Fosun Pharma for TEV-56278
Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed …
-
NextCure and Simcere partner to develop SIM0505 for solid tumours
NextCure has entered a strategic partnership with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, to develop SIM0505, a new …
-
Supernus makes depression drug play with $795m Sage buyout
Fewer than five months after rejecting a takeover approach by Biogen, Sage Therapeutics has found a buyer in Supernus Pharmaceuticals. According …
-
FDA approves MSD’s Keytruda to treat head and neck cancer
MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for …
-
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in …
-
Sarepta and Roche halt DMD gene therapy’s use after second death
Serepta and global partner Roche have discontinued the commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys …
-
Ethris and Thermo Fisher partner on mRNA solutions
Ethris has entered a strategic partnership with Thermo Fisher Scientific to provide a completely integrated messenger ribonucleic acid (mRNA) solution …
-
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June to 15 June in Milan, …
-
NICE approves GSK’s belantamab mafodotin for blood cancer
The National Health Service (NHS) England is set to become the first health system globally to offer the "Trojan horse" …
